Azimilide Dihydrochloride

DRUG7 trials

Sponsors

Forest Laboratories

Conditions

ArrhythmiaArrhythmiasArrhythmias, CardiacAtrial FibrillationCardiovascular DiseasesHealthyHeart DiseasesImplantable Cardioverter Defibrillator

Phase 1

Effect of Azimilide Dihydrochloride on Renal Function

CompletedNCT00318838

Forest LaboratoriesHealthy

Start: 2006-04-30End: 2006-05-31Updated: 2017-02-01

Phase 3

Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

CompletedNCT00035464

Forest LaboratoriesAtrial Fibrillation

Start: 2000-12-31End: 2004-01-31Updated: 2011-10-03

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

CompletedNCT00035490

Forest LaboratoriesArrhythmia

Start: 2001-09-30End: 2004-04-30Updated: 2011-10-03

Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

CompletedNCT00035477

Forest LaboratoriesAtrial Fibrillation

Start: 2000-09-30End: 2003-10-31Updated: 2011-10-03

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

CompletedNCT00035451

Forest LaboratoriesAtrial Fibrillation

Start: 2001-02-28End: 2003-06-30Updated: 2011-10-03

Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

CompletedNCT00751738

Forest LaboratoriesArrhythmias

Start: 2002-10-31End: 2005-10-31Updated: 2017-02-01

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

TerminatedNCT01464476

Forest LaboratoriesArrhythmias, Cardiac, Cardiovascular Diseases, Heart Diseases +1

Start: 2011-11-30End: 2013-06-30Updated: 2013-05-06